Search by Drug Name or NDC
NDC 00002-4182-61 Olumiant 2 mg/1 Details
Olumiant 2 mg/1
Olumiant is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eli Lilly and Company. The primary component is BARICITINIB.
MedlinePlus Drug Summary
Baricitinib is used alone or with other medications to treat rheumatoid arthritis (condition in which the body attacks its own joints causing pain, swelling, and loss of function) in adults who have not responded well to one or more tumor necrosis factor (TNF) inhibitor medication(s). It is also used for the treatment of coronavirus disease 2019 (COVID-19 infection) in hospitalized adults who require supplemental oxygen, a ventilator, or who need extracorporeal membrane oxygenation (ECMO; a device that adds oxygen to the blood). Baricitinib is also used to treat alopecia areata (a condition in which the body attacks hair follicles and causes hair loss) in adults. Baricitinib is in a class of medications called Janus kinase (JAK) inhibitors. It works by decreasing the activity of the immune system.
Related Packages: 00002-4182-61Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Baricitinib
Product Information
| NDC | 00002-4182 |
|---|---|
| Product ID | 0002-4182_44ded0f7-8c82-4875-ad44-db5b0354a094 |
| Associated GPIs | 66603010000320 |
| GCN Sequence Number | 077445 |
| GCN Sequence Number Description | baricitinib TABLET 2 MG ORAL |
| HIC3 | Z2Z |
| HIC3 Description | JANUS KINASE (JAK) INHIBITORS |
| GCN | 43468 |
| HICL Sequence Number | 044296 |
| HICL Sequence Number Description | BARICITINIB |
| Brand/Generic | Brand |
| Proprietary Name | Olumiant |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | baricitinib |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 2 |
| Active Ingredient Units | mg/1 |
| Substance Name | BARICITINIB |
| Labeler Name | Eli Lilly and Company |
| Pharmaceutical Class | Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA207924 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00002-4182-61 (00002418261)
| NDC Package Code | 0002-4182-61 |
|---|---|
| Billing NDC | 00002418261 |
| Package | 30 TABLET, FILM COATED in 1 BOTTLE (0002-4182-61) |
| Marketing Start Date | 2018-05-31 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |